Last €3.72 EUR
Change Today +0.54 / 16.80%
Volume 1.0K
JXS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Stuttgart
As of 11:11 AM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

orexigen therapeutics inc (JXS) Snapshot

Open
€3.11
Previous Close
€3.19
Day High
€3.72
Day Low
€3.10
52 Week High
06/11/14 - €5.50
52 Week Low
10/14/14 - €2.23
Market Cap
455.8M
Average Volume 10 Days
230.0
EPS TTM
--
Shares Outstanding
122.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OREXIGEN THERAPEUTICS INC (JXS)

orexigen therapeutics inc (JXS) Related Businessweek News

View More BusinessWeek News

orexigen therapeutics inc (JXS) Details

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include NB32, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic that has completed Phase II clinical trials. Orexigen Therapeutics, Inc. has collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize NB32 in the United States, Canada, and Mexico. The company was founded in 2002 and is headquartered in La Jolla, California.

50 Employees
Last Reported Date: 03/13/14
Founded in 2002

orexigen therapeutics inc (JXS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $625.0K
Acting Chief Financial Officer, Principal Acc...
Total Annual Compensation: $370.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $370.0K
Head of Global Contrave Program and Senior Vi...
Total Annual Compensation: $370.0K
Chief Commercial Officer
Total Annual Compensation: $296.0K
Compensation as of Fiscal Year 2013.

orexigen therapeutics inc (JXS) Key Developments

Orexigen Therapeutics and Takeda Pharmaceuticals Launch Sale of Contrave Weight Management Drug

Orexigen Therapeutics and its Takeda Pharmaceuticals have launched sales of Contrave extended-release tablets for chronic weight management in adults. The drug is now available by prescription in the U.S., approved by the U.S. Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) with at least one weight-related condition. Eligible patients taking Contrave will have access to the Scale Down program, which provides mobile weight management support and Contrave Direct Save, which provides the lowest cost available with home delivery.

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen Announce Availability of CONTRAVE(R)

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen(R) Therapeutics, Inc. jointly announced that Contrave(R) (naltrexone HCI and bupropion HCI) extended-release tablets are now available to patients by prescription in pharmacies across the United States. Contrave is approved by the U.S. Food and Drug Administration (FDA) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus or dyslipidemia). Eligible patients taking Contrave will have access to the Scale Down program, which provides mobile weight management support with a wireless scale that triggers daily personalised texts based on weigh-ins. In addition, eligible patients will have access to Contrave Direct Save, which provides the lowest cost available for both commercially insured and cash-paying patients, with one-on-one pharmacy support and the convenience of home delivery. When patients use the available savings offer, Contrave Direct Save provides progressive savings that begin on the third consecutive month of treatment if patients do not miss a refill. In addition to the Contrave Direct Save program, savings are also available to eligible patients through a Pharmacy Savings Card for those who prefer a retail pharmacy option.

Orexigen Therapeutics, Inc. Presents at Bank of America Merrill Lynch Global Healthcare Conference, Sep-18-2014 04:10 PM

Orexigen Therapeutics, Inc. Presents at Bank of America Merrill Lynch Global Healthcare Conference, Sep-18-2014 04:10 PM. Venue: Bank of America Merrill Lynch Financial Centre, London, United Kingdom.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JXS:GR €3.72 EUR +0.54

JXS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for JXS.
View Industry Companies
 

Industry Analysis

JXS

Industry Average

Valuation JXS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 139.7x
Price/Book 909.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 82.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OREXIGEN THERAPEUTICS INC, please visit www.orexigen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.